Forxiga label updated in the EU in type-2 diabetes
Label updated with positive cardiovascular outcomes and renal data from the DECLARE-TIMI 58 trialAstraZeneca today announced that the European Commission has approved an update to the marketing authorisation for Forxiga (dapagliflozin) to include positive cardiovascular (CV) outcomes and renal data from the Phase III DECLARE-TIMI 58 trial in adults with type-2 diabetes (T2D). The trial enrolled a majority of patients with no existing cardiovascular disease. Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D, said: “For patients with type-2 diabetes, heart failure is one of